$诺瓦瓦克斯医药 (NVAX.US)$ absolutely agree 
$280 then $420 coming 
load up boys and girls !

$诺瓦瓦克斯医药 (NVAX.US)$  The world still has a very long way to go !!!!

您认为哪种疫苗股票的上涨潜力最高？
示例包括辉瑞。 $辉瑞 (PFE.US)$ ，moderna。 $Moderna (MRNA.US)$ ，诺瓦瓦克斯医药。 $诺瓦瓦克斯医药 (NVAX.US)$

$诺瓦瓦克斯医药 (NVAX.US)$ 除了nvax申请韩国的BLA外，还有好消息。印度已批准SII向印度尼西亚出口5000万剂conovax疫苗。这意味着：1. SII确实有大规模生产能力，已生产至少1000万剂。2，只要得到其他国家的批准，SII也能够供应疫苗，包括英国、欧盟和澳洲等发达地区。理论上，eua批准没有障碍，只是在等待。

$诺瓦瓦克斯医药 (NVAX.US)$ good surge from 135 to 170. back to 300 ? awaiting some good news

$诺瓦瓦克斯医药 (NVAX.US)$ News: For all people who participated in clinical trials of Novavax vaccine in the UK and Mexico, the CDC in the United States accepts Novavax jabs as complete vaccinators.

$诺瓦瓦克斯医药 (NVAX.US)$ Not let go of less than 300

$诺瓦瓦克斯医药 (NVAX.US)$ From the perspective of long-term investment in stocks, this stock only needs to pass the WHO. It has long-term (1-2 years) holding value. Now we analyze the price-earnings ratio. Currently bntx is 11 times and mrna is 13 times. Nvax is expected to produce 2 billion doses next year. The current conservative order has 1.7 billion doses, and the front media reported that it will be 20 US dollars. We conservatively estimate that $10 is good, and there will be 17 billion in revenue. After deducting costs and management and consumption expenses, a surplus of 6.8 billion is calculated based on a 40% profit. After deducting the loss of about US$20 per share (74.48 million shares) in these years, the loss is about 1.6 billion. After deducting 1.6 billion, there will be a surplus of 5.2 billion. If calculated at 5 billion, the earnings per share is about 60 US dollars. The current price-to-earnings ratio of 160 is only 2.6 times. So in addition to technical lines, you should also think about its investment value.

$诺瓦瓦克斯医药 (NVAX.US)$ 到月球 https://seekingalpha.com/article/4466338-novavax-cranks-it-up-a-billion-more-doses-covid-authorization-and-much-more